Global Blood Therapeutics Announces Closing Of Initial Public Offering And Exercise Of Over-Allotment Option

SOUTH SAN FRANCISCO, CA--(Marketwired - August 17, 2015) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the closing of its initial public offering of 6,900,000 shares of common stock at an initial public offering price of $20.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock. All of the shares in the offering were offered by GBT. The company's common stock is listed on the NASDAQ Global Select Market under the ticker symbol "GBT." Global Blood Therapeutics estimates net proceeds from the offering to be approximately $126.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Morgan Stanley and Goldman, Sachs & Co. acted as joint book-running managers for the offering. Cowen and Company and Wedbush PacGrow acted as co-managers.

A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on August 11, 2015. Copies of the final prospectus relating to this offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 803-9204 or by email at prospectus@morganstanley.com or from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, Facsimile (212) 902-9316 or emailing prospectus.ny@ny.email.gs.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc. (GBT) is a clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its initial product candidate, GBT440, as an oral, once-daily prophylactic therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial. In addition to GBT440 for the treatment of SCD, GBT is engaged in research and development activities targeted toward hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF), and hereditary angioedema (HAE).